Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.

Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A.

PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016. Review.

2.

A literature review on the patients with autoimmune diseases following vaccination against infections.

Liang Y, Meng FY, Pan HF, Ye DQ.

Hum Vaccin Immunother. 2015;11(9):2274-80. doi: 10.1080/21645515.2015.1009337. Review.

3.

Successes and challenges in varicella vaccine.

Papaloukas O, Giannouli G, Papaevangelou V.

Ther Adv Vaccines. 2014 Mar;2(2):39-55. doi: 10.1177/2051013613515621. Review.

4.

Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Langan SM, Smeeth L, Margolis DJ, Thomas SL.

PLoS Med. 2013;10(4):e1001420. doi: 10.1371/journal.pmed.1001420. Epub 2013 Apr 9.

5.

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR.

JAMA. 2012 Jul 4;308(1):43-9. doi: 10.1001/jama.2012.7304.

6.

Immune correlates of herpes zoster in HIV-infected children and youth.

Weinberg A, Huang S, Song LY, Fenton T, Williams P, Patterson J, Tovar-Salazar A, Levin MJ.

J Virol. 2012 Mar;86(5):2878-81. doi: 10.1128/JVI.06623-11. Epub 2011 Dec 14.

7.

The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.

Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, Fernandes J, Chen L, Winthrop K, Curtis JR.

Arthritis Res Ther. 2011;13(5):R174. doi: 10.1186/ar3497. Epub 2011 Oct 24.

8.

Perspectives on vaccines against varicella-zoster virus infections.

Gershon AA, Gershon MD.

Curr Top Microbiol Immunol. 2010;342:359-72. doi: 10.1007/82_2010_12.

9.

Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan IS, Vessey R, Silber JL, MacGregor RR, Chan K, Gershon AA, Levin MJ.

J Infect Dis. 2010 Apr 1;201(7):1024-30. doi: 10.1086/651199.

Supplemental Content

Support Center